EGI
ABEO icon

EAM Global Investors’s Abeona Therapeutics ABEO Stock Holding History

EAM Global Investors’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,166
Closed -$858K – 136
2017
Q4 		$858K Buy
+2,166
New +$896K 0.44% 111

Other funds holding ABEO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM Global Investors's ABEO Position: Q1 2018 in Review

EAM Global Investors sold out of Abeona Therapeutics (ABEO) in Q1 2018, closing a stake of 2,166 shares — an estimated $858K sold.

EAM Global Investors first reported a position in ABEO in Q4 2017 and held it in 1 quarter. The position peaked at $858K in Q4 2017. 88 funds tracked by Wall St. Rank hold ABEO as of Q1 2018.

  • EAM Global Investors reported no remaining Abeona Therapeutics position as of Q1 2018 after selling out during the quarter.
  • EAM Global Investors sold 2,166 Abeona Therapeutics shares in Q1 2018, an estimated $858K.
  • EAM Global Investors first reported a position in Abeona Therapeutics in Q4 2017 and held it in 1 quarter.
  • EAM Global Investors's Abeona Therapeutics position peaked at $858K in Q4 2017.
  • 88 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2018.

Based on EAM Global Investors's 13F filing for Q1 2018, filed 4 Jun 2018.